XML 97 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Significant transactions (Details)
€ in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 8 Months Ended 10 Months Ended 12 Months Ended 101 Months Ended
Jun. 15, 2021
USD ($)
Feb. 03, 2020
USD ($)
Jun. 30, 2021
EUR (€)
Jun. 30, 2021
USD ($)
May 31, 2021
USD ($)
study
Mar. 31, 2021
USD ($)
Jul. 31, 2020
Mar. 31, 2019
EUR (€)
Jan. 31, 2019
USD ($)
patient
Oct. 31, 2018
EUR (€)
Jul. 31, 2018
EUR (€)
Mar. 31, 2021
USD ($)
Jun. 30, 2021
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
EUR (€)
Dec. 31, 2019
EUR (€)
Dec. 31, 2016
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
Aug. 31, 2012
USD ($)
Disclosure of transactions between related parties [line items]                                                  
Increase in loans and conditional advances | €                               € 0   € 10,350 € 14,000            
Prepaid expenses | €                               2,213   2,217              
LianBio, NBTXR3                                                  
Disclosure of transactions between related parties [line items]                                                  
Number of global registrational studies supported | study         5                                        
Upfront payment received $ 20,000   € 16,500 $ 20,000                   $ 20,000                      
LianBio, NBTXR3 | Maximum                                                  
Disclosure of transactions between related parties [line items]                                                  
Potential development and commercial milestones payments         $ 220,000                                     $ 220,000  
PharmaEngine, NBTWR3                                                  
Disclosure of transactions between related parties [line items]                                                  
Upfront payment received                                           $ 1,000      
Development milestones payments received                                       $ 1,000 $ 1,000        
Total payments received under agreement                                             $ 3,000    
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3                                                  
Disclosure of transactions between related parties [line items]                                                  
Upfront payment         $ 4,000 $ 2,500             € 5,400   $ 6,500 5,400 $ 6,500                
Milestone payment upon receipt of clinical study reports           1,000           $ 1,000                          
Milestone payment upon second regulatory approval           $ 5,000           $ 5,000                          
Royalties agreement, period           10 years           10 years                          
MD Anderson Cancer Center, NBTXR3                                                  
Disclosure of transactions between related parties [line items]                                                  
Upfront payment   $ 1,000             $ 1,000                                
Number of patients | patient                 340                                
Contractual capital commitments                 $ 11,000                                
Milestone payment, deferment period                 6 months                                
Prepaid expenses | €                               € 1,000   € 1,600              
EIB fixed rate loan                                                  
Disclosure of transactions between related parties [line items]                                                  
Royalties agreement, period                     6 years                            
Increase in loans and conditional advances | €               € 14,000   € 16,000                              
Borrowings, interest rate               5.00%   6.00%               4.00%              
Borrowing, maturity                                   5 years              
Undrawn borrowing facilities | €                                   € 10,000              
Borrowing, deferment period                                   1 year              
Borrowing, deferment period to request funds             12 months                                    
EIB fixed rate loan | Maximum                                                  
Disclosure of transactions between related parties [line items]                                                  
Notional amount | €                     € 40,000                            
Top of range | PharmaEngine, NBTWR3                                                  
Disclosure of transactions between related parties [line items]                                                  
Potential development and commercial milestones payments                                                 $ 56,000
Top of range | MD Anderson Cancer Center, NBTXR3                                                  
Disclosure of transactions between related parties [line items]                                                  
Milestone payment increase                                 16,400                
Top of range | EIB fixed rate loan                                                  
Disclosure of transactions between related parties [line items]                                                  
Notional amount | €                     € 40,000                            
Bottom of range | MD Anderson Cancer Center, NBTXR3                                                  
Disclosure of transactions between related parties [line items]                                                  
Milestone payment increase                                 $ 2,200